サマリー

代謝性疾患治療薬は、ヒトの代謝性疾患を治療するために使用されます。代謝疾患は主にグリコーゲン代謝疾患、脂質代謝疾患、アミノ酸代謝疾患、金属代謝疾患などを対象としています。
市場の分析と洞察。代謝異常治療薬の世界市場
代謝異常治療の世界市場規模は、2021年の100万米ドルから2028年には100万米ドルに達すると予測され、2022年から2028年の間にCAGR（年平均成長率）％で推移します。
この健康危機による経済変化を十分に考慮し、2021年に代謝障害治療世界市場の％を占めたグリコーゲン代謝疾患薬は、2028年までに100万米ドルの価値を持ち、COVID-19後の期間に改訂された％のCAGRで成長すると予測されます。一方、病院セグメントは、この予測期間を通して％CAGRに変更されています。

中国の代謝異常治療市場規模は2021年に100万米ドル、北米と欧州の代謝異常治療市場規模はそれぞれ100万米ドル、100万米ドルとされています。北米の割合は2021年に％、中国とヨーロッパはそれぞれ％、％で、中国の割合は2028年に％に達すると予測され、分析期間を通じてCAGR％で、追跡しています。日本、韓国、東南アジアはアジアで注目すべき市場であり、今後6年間のCAGRはそれぞれ％、％、％となっています。ヨーロッパの代謝異常治療の展望については、ドイツは2028年までに100万米ドルに達すると予測され、予測期間中のCAGRは%となっています。
本レポートは、業界標準の分析精度と高いデータ整合性により、世界の代謝異常治療市場で利用可能な主要機会を明らかにし、プレイヤーが市場で強力な地位を獲得するのに役立つ素晴らしい試みを行っています。本レポートの購入者は、世界の代謝異常治療市場の全体規模（収益ベース）を含む、検証済みで信頼性の高い市場予測にアクセスすることができます。

全体として、本レポートは、プレイヤーが競合他社に対する競争力を獲得し、世界の代謝異常治療市場で永続的な成功を収めるために使用できる効果的なツールであることが証明されています。本レポートで提供されるすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証され、再確認されたものです。本レポートを執筆したアナリストは、世界の代謝異常治療市場を詳細に調査するため、独自の業界最高水準の調査・分析アプローチを採用しています。

世界の代謝異常治療の範囲と市場規模
代謝異常治療市場は、プレイヤー別、地域（国）別、タイプ別、用途別に分類されます。代謝異常治療の世界市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別、アプリケーション別の収益と予測に焦点を当てます。

タイプ別セグメント
グリコーゲン代謝異常症治療薬
脂質代謝疾患治療薬
アミノ酸代謝改善剤
その他
用途別セグメント
病院
小売店

会社別
メルク
ノバルティス
武田薬品工業
アストラゼネカ
ベーリンガーインゲルハイム
興和
カイテラ
富士薬品
LGライフサイエンス
田辺三菱製薬

地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
北欧諸国
その他の欧州地域
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア
ラテンアメリカ
メキシコ
ブラジル
ラテンアメリカの残りの地域
中近東・アフリカ
トルコ
サウジアラビア
UAE
MEAの残りの地域

ページTOPに戻る

目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorders Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global Metabolic Disorders Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorders Treatment Market Perspective (2017-2028)
2.2 Metabolic Disorders Treatment Growth Trends by Region
2.2.1 Metabolic Disorders Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metabolic Disorders Treatment Historic Market Size by Region (2017-2022)
2.2.3 Metabolic Disorders Treatment Forecasted Market Size by Region (2023-2028)
2.3 Metabolic Disorders Treatment Market Dynamics
2.3.1 Metabolic Disorders Treatment Industry Trends
2.3.2 Metabolic Disorders Treatment Market Drivers
2.3.3 Metabolic Disorders Treatment Market Challenges
2.3.4 Metabolic Disorders Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorders Treatment Players by Revenue
3.1.1 Global Top Metabolic Disorders Treatment Players by Revenue (2017-2022)
3.1.2 Global Metabolic Disorders Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Metabolic Disorders Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorders Treatment Revenue
3.4 Global Metabolic Disorders Treatment Market Concentration Ratio
3.4.1 Global Metabolic Disorders Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Treatment Revenue in 2021
3.5 Metabolic Disorders Treatment Key Players Head office and Area Served
3.6 Key Players Metabolic Disorders Treatment Product Solution and Service
3.7 Date of Enter into Metabolic Disorders Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorders Treatment Breakdown Data by Type
4.1 Global Metabolic Disorders Treatment Historic Market Size by Type (2017-2022)
4.2 Global Metabolic Disorders Treatment Forecasted Market Size by Type (2023-2028)
5 Metabolic Disorders Treatment Breakdown Data by Application
5.1 Global Metabolic Disorders Treatment Historic Market Size by Application (2017-2022)
5.2 Global Metabolic Disorders Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metabolic Disorders Treatment Market Size (2017-2028)
6.2 North America Metabolic Disorders Treatment Market Size by Type
6.2.1 North America Metabolic Disorders Treatment Market Size by Type (2017-2022)
6.2.2 North America Metabolic Disorders Treatment Market Size by Type (2023-2028)
6.2.3 North America Metabolic Disorders Treatment Market Share by Type (2017-2028)
6.3 North America Metabolic Disorders Treatment Market Size by Application
6.3.1 North America Metabolic Disorders Treatment Market Size by Application (2017-2022)
6.3.2 North America Metabolic Disorders Treatment Market Size by Application (2023-2028)
6.3.3 North America Metabolic Disorders Treatment Market Share by Application (2017-2028)
6.4 North America Metabolic Disorders Treatment Market Size by Country
6.4.1 North America Metabolic Disorders Treatment Market Size by Country (2017-2022)
6.4.2 North America Metabolic Disorders Treatment Market Size by Country (2023-2028)
6.4.3 the United States
6.4.4 Canada
7 Europe
7.1 Europe Metabolic Disorders Treatment Market Size (2017-2028)
7.2 Europe Metabolic Disorders Treatment Market Size by Type
7.2.1 Europe Metabolic Disorders Treatment Market Size by Type (2017-2022)
7.2.2 Europe Metabolic Disorders Treatment Market Size by Type (2023-2028)
7.2.3 Europe Metabolic Disorders Treatment Market Share by Type (2017-2028)
7.3 Europe Metabolic Disorders Treatment Market Size by Application
7.3.1 Europe Metabolic Disorders Treatment Market Size by Application (2017-2022)
7.3.2 Europe Metabolic Disorders Treatment Market Size by Application (2023-2028)
7.3.3 Europe Metabolic Disorders Treatment Market Share by Application (2017-2028)
7.4 Europe Metabolic Disorders Treatment Market Size by Country
7.4.1 Europe Metabolic Disorders Treatment Market Size by Country (2017-2022)
7.4.2 Europe Metabolic Disorders Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorders Treatment Market Size (2017-2028)
8.2 Asia-Pacific Metabolic Disorders Treatment Market Size by Type
8.2.1 Asia-Pacific Metabolic Disorders Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Metabolic Disorders Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Metabolic Disorders Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Metabolic Disorders Treatment Market Size by Application
8.3.1 Asia-Pacific Metabolic Disorders Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Metabolic Disorders Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Metabolic Disorders Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Metabolic Disorders Treatment Market Size by Region
8.4.1 Asia-Pacific Metabolic Disorders Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Metabolic Disorders Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Metabolic Disorders Treatment Market Size (2017-2028)
9.2 Latin America Metabolic Disorders Treatment Market Size by Type
9.2.1 Latin America Metabolic Disorders Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Metabolic Disorders Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Metabolic Disorders Treatment Market Share by Type (2017-2028)
9.3 Latin America Metabolic Disorders Treatment Market Size by Application
9.3.1 Latin America Metabolic Disorders Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Metabolic Disorders Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Metabolic Disorders Treatment Market Share by Application (2017-2028)
9.4 Latin America Metabolic Disorders Treatment Market Size by Country
9.4.1 Latin America Metabolic Disorders Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Metabolic Disorders Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorders Treatment Market Size (2017-2028)
10.2 Middle East & Africa Metabolic Disorders Treatment Market Size by Type
10.2.1 Middle East & Africa Metabolic Disorders Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Metabolic Disorders Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Metabolic Disorders Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Metabolic Disorders Treatment Market Size by Application
10.3.1 Middle East & Africa Metabolic Disorders Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Metabolic Disorders Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Metabolic Disorders Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Metabolic Disorders Treatment Market Size by Country
10.4.1 Middle East & Africa Metabolic Disorders Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Metabolic Disorders Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Metabolic Disorders Treatment Introduction
11.1.4 Merck Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.1.5 Merck Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Metabolic Disorders Treatment Introduction
11.2.4 Novartis Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.2.5 Novartis Recent Developments
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Details
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Metabolic Disorders Treatment Introduction
11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.3.5 Takeda Pharmaceutical Recent Developments
11.4 Astra Zeneca
11.4.1 Astra Zeneca Company Details
11.4.2 Astra Zeneca Business Overview
11.4.3 Astra Zeneca Metabolic Disorders Treatment Introduction
11.4.4 Astra Zeneca Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.4.5 Astra Zeneca Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Metabolic Disorders Treatment Introduction
11.5.4 Boehringer Ingelheim Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.5.5 Boehringer Ingelheim Recent Developments
11.6 KOWA
11.6.1 KOWA Company Details
11.6.2 KOWA Business Overview
11.6.3 KOWA Metabolic Disorders Treatment Introduction
11.6.4 KOWA Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.6.5 KOWA Recent Developments
11.7 Kythera
11.7.1 Kythera Company Details
11.7.2 Kythera Business Overview
11.7.3 Kythera Metabolic Disorders Treatment Introduction
11.7.4 Kythera Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.7.5 Kythera Recent Developments
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Company Details
11.8.2 Fuji yakuhin Business Overview
11.8.3 Fuji yakuhin Metabolic Disorders Treatment Introduction
11.8.4 Fuji yakuhin Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.8.5 Fuji yakuhin Recent Developments
11.9 LG Life Science
11.9.1 LG Life Science Company Details
11.9.2 LG Life Science Business Overview
11.9.3 LG Life Science Metabolic Disorders Treatment Introduction
11.9.4 LG Life Science Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.9.5 LG Life Science Recent Developments
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Company Details
11.10.2 Metsubishi Tanabe Pharma Business Overview
11.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Treatment Introduction
11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disorders Treatment Business (2017-2022)
11.10.5 Metsubishi Tanabe Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer